Ⅰ-Ⅱ期结节性淋巴细胞为主型霍奇金淋巴瘤多中心研究
该多中心回顾性研究纳入1995-2018年诊断的559例≥16岁Ⅰ-Ⅱ期结节性淋巴细胞为主型霍奇金淋巴瘤患者,中位随访5.5年,全队列5年无进展生存率和总生存率分别为87.1%和98.3%,所有治疗方式后总生存均优异。
要点
- 全队列5年无进展生存率和总生存率分别为87.1%和98.3%。
- 单纯放疗后5年无进展生存率为91.1%,化放疗联合为90.5%。
- 变异免疫架构模式和受累部位数>2与更差无进展生存相关。
核心结论
- Ⅰ-Ⅱ期结节性淋巴细胞为主型霍奇金淋巴瘤患者在所有治疗方式后总生存均优异。
研究设计与样本
- 多中心回顾性研究纳入1995-2018年诊断的559例≥16岁Ⅰ-Ⅱ期结节性淋巴细胞为主型霍奇金淋巴瘤患者。
主要发现
- 中位年龄39岁,72.3%为男性,54.9%为Ⅰ期,中位随访5.5年(四分位距3.1-10.1)。
- 全队列5年无进展生存率和总生存率分别为87.1%和98.3%。
- 主要治疗为单纯放疗(n=257,46.0%)、化放疗联合(n=184,32.9%)、单纯化疗(n=47,8.4%)、观察(n=37,6.6%)、利妥昔单抗联合放疗(n=19,3.4%)和单药利妥昔单抗(n=15,2.7%)。
- 5年无进展生存率:放疗后91.1%,化放疗联合后90.5%,化疗后77.8%,观察后73.5%,利妥昔单抗联合放疗后80.8%,单药利妥昔单抗后38.5%。
- 在放疗队列中,变异免疫架构模式和受累部位数>2与更差无进展生存相关(P<.05)。
临床怎么用
- Ⅰ-Ⅱ期结节性淋巴细胞为主型霍奇金淋巴瘤治疗选择需个体化,单纯放疗和化放疗联合均显示较高5年无进展生存率。
局限性
- 研究为回顾性设计,未对各治疗组进行统计学比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic variant, and the optimal treatment of stage I-II NLPHL is undefined. We conducted a multicenter retrospective study including patients ≥16 years of age with stage I-II NLPHL diagnosed from 1995 through 2018 who underwent all forms of management, including radiotherapy (RT), combined modality therapy (CMT; RT+chemotherapy [CT]), CT, observation after excision, rituximab and RT, and single-agent rituximab. End points were progression-free survival (PFS), freedom from transformation, and overall survival (OS) without statistical comparison between management groups. We identified 559 patients with median age of 39 years: 72.3% were men, and 54.9% had stage I disease. Median follow-up was 5.5 years (interquartile range, 3.1-10.1). Five-year PFS and OS in the entire cohort were 87.1% and 98.3%, respectively. Primary management was RT alone (n = 257; 46.0%), CMT (n = 184; 32.9%), CT alone (n = 47; 8.4%), observation (n = 37; 6.6%), rituximab and RT (n = 19; 3.4%), and rituximab alone (n = 15; 2.7%). The 5-year PFS rates were 91.1% after RT, 90.5% after CMT, 77.8% after CT, 73.5% after observation, 80.8% after rituximab and RT, and 38.5% after rituximab alone. In the RT cohort, but not the CMT cohort, variant immunoarchitectural pattern and number of sites >2 were associated with worse PFS (P < .05). Overall, 21 patients (3.8%) developed large-cell transformation, with a significantly higher transformation rate in those with variant immunoarchitectural pattern (P = .049) and number of involved sites >2 (P = .0006). OS for patients with stage I-II NLPHL was excellent after all treatments.
引用
- Binkley MS, Rauf MS, Milgrom SA, et al. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood. 2020. PMID: 32211877. doi:10.1182/blood.2019003877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。